PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · Clinician

CagriSema Dr EXPLAINS How This GLP 1 + Amylin Drug Differs From Wegovy

Clinician7:53Feb 2026

Today’s cheapest Wegovy$208/mo at Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly.Compare all Wegovy prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

According to the video, CagriSema is an investigational weekly injection that combines two drugs in one fixed dose: semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analog that also activates calcitonin receptors. The doctor explains that this is not a stronger GLP-1 but a strategy that uses two satiety pathways, and that it differs from Wegovy because Wegovy is semaglutide alone.

Published by Dr. G's Lifestyle Medicine Network on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The doctor reviews the trial reports. In the REDEFINE 1 phase 3 trial, adults with obesity or overweight and no type 2 diabetes were followed for 68 weeks, and the highest efficacy analysis showed average weight loss of up to about 22.7% with the full dose regimen. In REDEFINE 2, in people with type 2 diabetes, public reports described weight loss of around 15.7% in certain analyses. The doctor notes that people with diabetes often lose less weight on the same therapy, and that averages are shaped by dose escalation, adherence and discontinuation. He also says early 2026 reporting from the REIMAGINE 2 trial found CagriSema lowered hemoglobin A1C and body weight more than semaglutide alone in type 2 diabetes.

On safety, the doctor lists nausea, vomiting, diarrhea, constipation, reflux and reduced appetite as the most discussed side effects, mostly during dose escalation, and mentions dehydration and low energy as risks. He stresses protein, micronutrients, resistance training, hydration and monitoring to protect muscle, especially in older adults. He describes CagriSema as still evolving, with long-term durability and real-world tolerability yet to be settled, and says the decision about who should use it is individualized.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:00 The doctor says CagriSema combines semaglutide and cagrilintide, an amylin analog, in one weekly injection, while Wegovy is semaglutide alone.
  2. 1:33 He cites REDEFINE 1 (68 weeks, no diabetes) with average weight loss of up to about 22.7% at the full dose regimen.
  3. 2:05 He cites REDEFINE 2 in type 2 diabetes with weight loss around 15.7% in certain analyses, which he says is typical of smaller losses in people with diabetes.
  4. 3:36 He reports early 2026 REIMAGINE 2 results showing greater A1C and weight reduction than semaglutide alone in type 2 diabetes.
  5. 4:36 He lists gastrointestinal effects, dehydration and low energy as the main side effects, mostly during dose escalation, and stresses protein and resistance training.
  6. 5:37 He says CagriSema is still investigational and that long-term data and real-world tolerability will determine its role.

Key moments

Tap one to play from there.

  1. 0:00 Introduction to Kagrama
  2. 0:21 Mechanism of action
  3. 1:34 Clinical trial data
  4. 3:14 Outperforming monotherapy
  5. 4:04 Patient impact and limits
  6. 4:42 Safety and health management
  7. 5:49 Future and implementation
  8. 6:55 Takeaways and contact

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy and semaglutide

Questions this video answers

How is CagriSema different from Wegovy?

According to the video, Wegovy is semaglutide alone, while CagriSema is semaglutide plus cagrilintide, an amylin analog. The doctor describes it as adding a second satiety pathway rather than being a stronger GLP-1.

How much weight loss did CagriSema show in the REDEFINE trials?

The doctor says REDEFINE 1, in adults without type 2 diabetes over 68 weeks, showed average weight loss of up to about 22.7% with the full dose regimen. He says REDEFINE 2, in people with type 2 diabetes, was described in public reports as around 15.7% in certain analyses.

What are the side effects of CagriSema?

The doctor says the most discussed side effects are nausea, vomiting, diarrhea, constipation, reflux and decreased appetite, mostly during dose escalation. He also mentions dehydration and low energy if people do not eat and drink enough.

Is CagriSema approved yet?

The doctor describes CagriSema as investigational and still working through large clinical programs. He does not give an availability date in the video.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Wegovy 7.2 mg (Wegovy HD): what the higher dose adds, and what it costs

    Wegovy HD is semaglutide at 7.2 mg, three times the standard 2.4 mg dose, in its own pen. In the STEP UP trial it took 18.7% off body weight at 72 weeks against 15.6% for 2.4 mg and 3.9% for placebo, in 1,407 adults with obesity. That puts it within 1.5 points of tirzepatide's head-to-head result and makes it the strongest semaglutide there is. Novo sells it direct for $399 a month, $50 above the standard pen, and it sits above the normal ladder rather than replacing it.

  • Wegovy side effects, and why the top of the ladder is different

    Wegovy's side effects are semaglutide's side effects: nausea, vomiting, diarrhoea and constipation, worst in the first weeks and after each dose increase. What makes Wegovy different from Ozempic is not the molecule but the destination. Wegovy is dosed for weight management, climbing to 2.4 mg with a 7.2 mg high-dose strength above it, and dose is the main driver of how pronounced the gastrointestinal effects get. It also carries a boxed warning for thyroid C-cell tumour risk. One useful fact while you decide whether to push through: Novo's self-pay price is flat across every pen dose, so a slower climb costs a brand patient nothing.

  • Semaglutide for weight loss: which version, and what each costs

    Semaglutide is the molecule. For weight loss the FDA-approved version is Wegovy, sold as a weekly pen and a daily tablet. Ozempic is the same molecule approved for type 2 diabetes, so using it for weight is off-label. Compounded semaglutide uses semaglutide as its active ingredient, comes from a compounding pharmacy, is not FDA-approved, and is what most cash buyers actually take because it costs a fraction of the brand. All three produce the same side effects. What differs is the approval, the oversight and the price.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeFood, protein and eatingFood noise and cravingsHow it worksThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV